Growth Metrics

Palvella Therapeutics (PVLA) Cash from Operations (2016 - 2026)

Palvella Therapeutics has reported Cash from Operations over the past 10 years, most recently at 12933000.0 for Q4 2022.

  • Quarterly Cash from Operations fell 18.17% to 12933000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was 59932000.0 through Dec 2022, down 682.4% year-over-year, with the annual reading at 25006000.0 for FY2025, 130.68% down from the prior year.
  • Cash from Operations was 12933000.0 for Q4 2022 at Palvella Therapeutics, down from 8778000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 31339000.0 in Q1 2018 and troughed at 22643000.0 in Q1 2022.
  • The 5-year median for Cash from Operations is 12395000.0 (2019), against an average of 8351050.0.
  • Year-over-year, Cash from Operations skyrocketed 405.85% in 2021 and then tumbled 152.09% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 9058000.0 in 2018, then tumbled by 54.27% to 13974000.0 in 2019, then grew by 3.99% to 13417000.0 in 2020, then grew by 18.43% to 10944000.0 in 2021, then fell by 18.17% to 12933000.0 in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Cash from Operations are 12933000.0 (Q4 2022), 8778000.0 (Q3 2022), and 15578000.0 (Q2 2022).